Last week the U.S. corporation Monsanto, which holds a leading position in the global market of genetically modified organisms (GMOs), reached a licensing agreement with the Broad Institute, Cambridge, USA, on the commercial use of the innovative genome-editing technology CRISPR/Cas9 for agriculture applications. This news has led some experts to